The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GPCR | +145.35% | N/A | N/A | +122% |
| S&P | +17.45% | +75.43% | +11.88% | +63% |
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$1,381.00K | 26.2% |
| Market Cap | $4.91B | 216.4% |
| Market Cap / Employee | $22.33M | 134.4% |
| Employees | 220 | 35.0% |
| Net Income | $33.15M | 191.2% |
| EBITDA | -$85,255.45K | -89.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $799.63M | 371.7% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.61M | 66.8% |
| Short Term Debt | $2.88M | 69.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -11.37% | 6.3% |
| Return On Invested Capital | -35.57% | 5.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$66,193.26K | -81.6% |
| Operating Free Cash Flow | -$64,691.89K | -77.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.15 | 1.45 | 2.09 | 5.48 | 216.54% |
| Price to Tangible Book Value | 1.15 | 1.45 | 2.09 | 5.48 | 216.54% |
| Enterprise Value to EBITDA | -2.93 | -5.94 | -11.60 | -31.41 | 109.80% |
| Return on Equity | -22.9% | -21.2% | -25.3% | -11.9% | -36.16% |
| Total Debt | $7.59M | $7.68M | $7.09M | $6.49M | 67.97% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
